Press release
Pulmonary Emphysema Market Expected to Experience Major Growth by 2032, According to DelveInsight | Aeris Therapeutics, Broncus Tech, Grifols Therapeutics, Hoffmann-La Roche
The latest healthcare forecast report provides an in-depth analysis of Pulmonary Emphysema, offering comprehensive insights into the Pulmonary Emphysema revenue trends, prevalence, and treatment landscape. The report delves into key Pulmonary Emphysema statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Pulmonary Emphysema therapies. Additionally, we cover the landscape of Pulmonary Emphysema clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Pulmonary Emphysema treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Pulmonary Emphysema space.
To Know in detail about the Pulmonary Emphysema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Emphysema Market Forecast
https://www.delveinsight.com/sample-request/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Pulmonary Emphysema Market Report:
• The Pulmonary Emphysema market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In January 2025, Aer Therapeutics (Aer), a biopharmaceutical company focused on developing innovative inhaled therapies for mucus-associated lung diseases, announced that the first patient has been dosed in its Phase 2a proof-of-concept (POC) clinical trial evaluating fexlamose (previously known as AER-01) for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
• Key Pulmonary Emphysema Companies: Aeris Therapeutics, Broncus Technologies, Grifols Therapeutics LLC, Hoffmann-La Roche, Mesoblast, Inc, Sanofi, and others
• Key Pulmonary Emphysema Therapies: BLVR Treatment, Exhale Drug-Eluting Stent, Alpha-1 MP, RAR Gamma, ProchymalTM, SAR447537, and others
• The Pulmonary Emphysema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Emphysema pipeline products will significantly revolutionize the Pulmonary Emphysema market dynamics.
Pulmonary Emphysema Overview
Pulmonary emphysema is a chronic lung condition characterized by the destruction of alveoli (air sacs) in the lungs, leading to reduced oxygen exchange and breathing difficulties. It is a form of chronic obstructive pulmonary disease (COPD) and is primarily caused by long-term smoking, air pollution, or genetic factors like alpha-1 antitrypsin deficiency. Symptoms include shortness of breath, chronic cough, wheezing, and fatigue. There is no cure, but treatments such as bronchodilators, corticosteroids, oxygen therapy, and pulmonary rehabilitation can help manage symptoms and improve quality of life.
Get a Free sample for the Pulmonary Emphysema Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pulmonary Emphysema Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Pulmonary Emphysema Epidemiology Segmentation:
The Pulmonary Emphysema market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Pulmonary Emphysema
• Prevalent Cases of Pulmonary Emphysema by severity
• Gender-specific Prevalence of Pulmonary Emphysema
• Diagnosed Cases of Episodic and Chronic Pulmonary Emphysema
Download the report to understand which factors are driving Pulmonary Emphysema epidemiology trends @ Pulmonary Emphysema Epidemiology Forecast
https://www.delveinsight.com/sample-request/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pulmonary Emphysema Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Emphysema market or expected to get launched during the study period. The analysis covers Pulmonary Emphysema market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pulmonary Emphysema Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Pulmonary Emphysema Therapies and Key Companies
• BLVR Treatment: Aeris Therapeutics
• Exhale Drug-Eluting Stent: Broncus Technologies
• Alpha-1 MP: Grifols Therapeutics LLC
• RAR Gamma: Hoffmann-La Roche
• ProchymalTM: Mesoblast, Inc
• SAR447537: Sanofi
Discover more about therapies set to grab major Pulmonary Emphysema market share @ Pulmonary Emphysema Treatment Landscape
https://www.delveinsight.com/sample-request/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Pulmonary Emphysema Market Drivers
• Rising Prevalence of COPD
• Growing Aging Population
• Advancements in Treatment
• Increased Awareness and Diagnosis
• Technological Innovations
• Government and Private Funding
• Rising Tobacco Consumption and Pollution Exposure
Pulmonary Emphysema Market Barriers
• High Treatment Costs
• Limited Curative Options
• Side Effects of Current Therapies
• Stringent Regulatory Approvals
• Lack of Awareness in Developing Regions
• Slow Adoption of New Technologies
• Impact of COVID-19 and Other Respiratory Diseases
Scope of the Pulmonary Emphysema Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pulmonary Emphysema Companies: Aeris Therapeutics, Broncus Technologies, Grifols Therapeutics LLC, Hoffmann-La Roche, Mesoblast, Inc, Sanofi, and others
• Key Pulmonary Emphysema Therapies: BLVR Treatment, Exhale Drug-Eluting Stent, Alpha-1 MP, RAR Gamma, ProchymalTM, SAR447537, and others
• Pulmonary Emphysema Therapeutic Assessment: Pulmonary Emphysema current marketed and Pulmonary Emphysema emerging therapies
• Pulmonary Emphysema Market Dynamics: Pulmonary Emphysema market drivers and Pulmonary Emphysema market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Pulmonary Emphysema Unmet Needs, KOL's views, Analyst's views, Pulmonary Emphysema Market Access and Reimbursement
To know more about Pulmonary Emphysema companies working in the treatment market, visit @ Pulmonary Emphysema Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/pulmonary-emphysema-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Pulmonary Emphysema Market Report Introduction
2. Executive Summary for Pulmonary Emphysema
3. SWOT analysis of Pulmonary Emphysema
4. Pulmonary Emphysema Patient Share (%) Overview at a Glance
5. Pulmonary Emphysema Market Overview at a Glance
6. Pulmonary Emphysema Disease Background and Overview
7. Pulmonary Emphysema Epidemiology and Patient Population
8. Country-Specific Patient Population of Pulmonary Emphysema
9. Pulmonary Emphysema Current Treatment and Medical Practices
10. Pulmonary Emphysema Unmet Needs
11. Pulmonary Emphysema Emerging Therapies
12. Pulmonary Emphysema Market Outlook
13. Country-Wise Pulmonary Emphysema Market Analysis (2019-2032)
14. Pulmonary Emphysema Market Access and Reimbursement of Therapies
15. Pulmonary Emphysema Market Drivers
16. Pulmonary Emphysema Market Barriers
17. Pulmonary Emphysema Appendix
18. Pulmonary Emphysema Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Latest Reports by DelveInsight
• Tinnitus Market: https://www.delveinsight.com/report-store/tinnitus-medical-devices-market
• Vutrisiran Market: https://www.delveinsight.com/report-store/vutrisiran-market
• Microscopy Device Market: https://www.delveinsight.com/report-store/microscopy-device-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market
• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Emphysema Market Expected to Experience Major Growth by 2032, According to DelveInsight | Aeris Therapeutics, Broncus Tech, Grifols Therapeutics, Hoffmann-La Roche here
News-ID: 3908019 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
